XTX Topco’s Kiniksa Pharmaceuticals KNSA Stock Holding History

XTX Topco’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,062	Closed	-$291K	–	4103
2025 Q4	$291K	Buy	+7,062	New	+$283K	0.01%	2097
2024 Q4	–	Sell	-27,302	Closed	-$682K	–	2620
2024 Q3	$682K	Buy	27,302 +10,474	+62%	+$255K	0.05%	613
2024 Q2	$314K	Buy	+16,828	New	+$315K	0.03%	928
2022 Q4	–	Sell	-16,807	Closed	-$216K	–	1322
2022 Q3	$216K	Buy	+16,807	New	+$191K	0.05%	734

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

XTX Topco's KNSA Position: Q1 2026 in Review

XTX Topco sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 7,062 shares — an estimated $291K sold.

XTX Topco first reported a position in KNSA in Q3 2022 and held it in 4 quarters. The position peaked at $682K in Q3 2024. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

XTX Topco reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
XTX Topco sold 7,062 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $291K.
XTX Topco first reported a position in Kiniksa Pharmaceuticals in Q3 2022 and held it in 4 quarters.
XTX Topco's Kiniksa Pharmaceuticals position peaked at $682K in Q3 2024.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.